Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. is demonstrating promising progress in its clinical pipeline, particularly with icovamenib, which achieved a significant 1.2% reduction in HbA1c in the severe insulin-deficient subgroup over 52 weeks, indicating strong potential for durable glycemic control in type 2 diabetes patients. The company has further enhanced its outlook with the advancement of BMF-650, an oral GLP-1 receptor agonist, which has shown effective dose-dependent weight reductions in preclinical studies, and its successful progression into Phase I trials. Additionally, Biomea Fusion's financial performance reflects improvement, as the company narrowed its net loss to $16.4 million for Q3 2025 from $32.8 million in the prior year, indicating effective cost management alongside strategic investment in its drug development pipeline.

Bears say

Biomea Fusion Inc. reported a significant decline in research and development expenses, decreasing from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, while general and administrative expenses also saw a reduction from $6.8 million to $4.2 million. The decrease in R&D spending may indicate challenges in advancing its product candidates and could impact the company’s long-term growth potential. Additionally, the adjustment in the price target from $16.00 to $12.00 reflects a negative outlook, suggesting a reassessment of the company’s financial health and strategic direction.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.